Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
24 nov. 2021 13h24 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) has received written notification (the "Nasdaq Notice")...
The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System
24 nov. 2021 09h34 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s...
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 16h21 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the third quarter...
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
01 nov. 2021 09h05 HE
|
Neovasc, Inc.
VANCOUVER, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021....
Neovasc Reducer™ Featured in Polish Heart Journal
21 oct. 2021 09h05 HE
|
Neovasc, Inc.
Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary Artery VANCOUVER and MINNEAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc....
Neovasc REDUCER-I Study Published in EuroIntervention Journal
28 sept. 2021 09h05 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article...
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
23 sept. 2021 09h05 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be...
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
16 sept. 2021 09h05 HE
|
Neovasc, Inc.
Company on Schedule to Commence Trial Late This Year VANCOUVER and MINNEAPOLIS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN)...
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
30 août 2021 16h05 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be...
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
17 août 2021 09h05 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the...